{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Subfoveal+Choroidal+Neovascularization",
    "query": {
      "condition": "Subfoveal Choroidal Neovascularization"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Subfoveal+Choroidal+Neovascularization&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T01:54:12.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03834753",
      "title": "A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-related Macular Degeneration",
        "Neovascular Age-related Macular Degeneration",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ranibizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Outlook Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2019-06-25",
      "completion_date": "2021-07-08",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 50,
      "location_summary": "Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03834753"
    },
    {
      "nct_id": "NCT00454389",
      "title": "A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Epi-Rad90™ Ophthalmic System",
          "type": "DEVICE"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NeoVista",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 494,
      "start_date": "2007-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2011-07-27",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454389"
    },
    {
      "nct_id": "NCT01833325",
      "title": "Proton Radiation Therapy for Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Proton radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2013-05",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01833325"
    },
    {
      "nct_id": "NCT00058994",
      "title": "An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Maculopathy, Age-Related"
      ],
      "interventions": [
        {
          "name": "anecortave acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-03",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-29",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058994"
    },
    {
      "nct_id": "NCT00242580",
      "title": "A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Verteporfin photodynamic therapy",
          "type": "DRUG"
        },
        {
          "name": "Pegaptanib",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-03-31",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00242580"
    },
    {
      "nct_id": "NCT00436553",
      "title": "Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Verteporfin Photodynamic Therapy",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Verteporfin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 321,
      "start_date": "2007-02",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2011-04-19",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436553"
    },
    {
      "nct_id": "NCT00363714",
      "title": "A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "AGN211745",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2004-11",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2008-08-18",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Cleveland, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363714"
    },
    {
      "nct_id": "NCT01175395",
      "title": "20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "IBI-20089/Lucentis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-09",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-10-20",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01175395"
    },
    {
      "nct_id": "NCT00259753",
      "title": "Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Bevasiranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2005-07",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-08-05",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00259753"
    },
    {
      "nct_id": "NCT00090623",
      "title": "A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "rhuFab V2 (ranibizumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2004-08",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-07-23T01:54:12.984Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090623"
    }
  ]
}